BCN Biosciences is focused on developing innovative small molecule drugs targeting oncology, specifically in the RAS and Immune Oncology domains. One of their key products, BCN077, addresses the suppression of the PTEN protein, a critical factor in RAS tumor biology. By restoring PTEN expression in RAS mutant cancers, particularly those with G12V and G12D mutations, BCN077 promotes rapid apoptosis, effectively circumventing resistance mechanisms associated with RAS inhibition. This approach highlights BCN's commitment to tackling the complexities of RAS-driven cancers and enhancing therapeutic efficacy.

Another significant development from BCN Biosciences is BCN176, a first-in-class small molecule that regulates PD-1 expression on T-lymphocytes. Unlike traditional methods that rely on antibodies to block the PD-1/PDL1 interaction, BCN176 employs T-box transcription factors to downregulate PD-1 expression in the tumor microenvironment, representing a novel strategy for checkpoint inhibition. Additionally, BCN512, part of the BCN500 series, is being investigated for its potential to mitigate radiation-induced lung and dermal fibrosis without compromising tumor integrity. Collectively, these technologies underscore BCN Biosciences' innovative approach to addressing critical challenges in cancer treatment.

United States

BCN Biosciences is a privately held pharmaceutical company with core competency in oncology drug development. BCN is currently developing novel small molecule drugs for the treatment of cancer.

BCN Biosciences

Company Details